Totect

Anthracycline extravasation happens - know how to respond.

DISCOVER the ANTIDOTE to anthracycline extravasation

  • The only FDA approved anthracycline extravasation antidote2
  • Highly effective in reducing tissue damage3
  • Eliminated the need for surgery in 98% of patients in clinical studies3
  • Allows for the majority of patients to continue their next scheduled dose of cancer therapy on time3,4

 

References:
1. Langer SW. Curr Oncol Rep. 2010 May;12:242-246. 2. TOTECT® [prescribing information]. Nashville, TN; Cumberland Pharmaceuticals; February 2018. 3. Mouridsen HT et al. Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21. 4. Fontaine C et al. Support Care Cancer. 2012 May;20(5):1109-12. doi:10.1007/s00520-012-1382-2. Epub 2012 Jan 27.
Know How To Respond

INDICATION: TOTECT® (dexrazoxane) is indicated for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.

IMPORTANT DOSAGE AND ADMINISTRATION INSTRUCTIONS
Vial contents must be reconstituted and diluted with 50 mL of 0.167 M sodium lactate injection solution and further mixed and diluted with the recommended dose in 1000 mL 0.9% Sodium Chloride before use. The TOTECT dose should be reduced by 50% in patients with creatinine clearance values < 40 mL/min.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS
Myelosuppression: TOTECT is associated with leukopenia, neutropenia, and thrombocytopenia. Perform hematological monitoring during treatment with TOTECT and cytotoxic chemotherapy as the myelosuppression and cytotoxic potential may be additive to that of chemotherapy alone.

Anaphylactic/Hypersensitivity Reactions: Hypersensitivity reactions including anaphylactic reaction, angioedema, skin reactions, bronchospasm, respiratory distress, hypotension and loss of consciousness have occurred in patients treated with dexrazoxane products and anthracyclines. Previous history of allergy to dexrazoxane products should be carefully considered prior to administration. Consider permanent discontinuation in patients with severe hypersensitivity reactions.

Embryo-Fetal Toxicity: TOTECT can cause fetal harm when administered to a pregnant woman. Advise patients of potential risk and to use effective contraception during treatment and 6 months following the last dose of TOTECT. Use in patients with hepatic impairment is not recommended.

DRUG INTERACTIONS
TOTECT is not recommended for use with dimethyl sulfoxide (DMSO).

ADVERSE REACTIONS
In the clinical studies, TOTECT was administered to patients also receiving chemotherapeutic agents for cancer, and the adverse reaction profile reflects the combination of TOTECT, underlying disease, and already administered chemotherapy. The most common adverse reactions (≥15%) are nausea, fever, injection site pain, vomiting, and postoperative infection.

Click here to view Full Prescribing Information